ProQR Therapeutics BV ( (PRQR) ) has released its Q1 earnings. Here is a breakdown of the information ProQR Therapeutics BV presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ProQR Therapeutics BV is a biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer RNA editing technology, targeting diseases with unmet medical needs. In its first-quarter 2025 earnings report, ProQR highlighted significant advancements in its Axiomer RNA editing pipeline, particularly in liver and central nervous system programs, and announced key leadership appointments. The company reported €132.4 million in cash and cash equivalents, providing financial runway into mid-2027, and achieved a milestone with its partner, Eli Lilly. ProQR’s financial performance showed a net loss of €10.1 million for the quarter, with increased research and development expenses reflecting its commitment to advancing its pipeline. Looking ahead, ProQR remains focused on executing its strategic goals, including the submission of a Clinical Trial Application for its lead program AX-0810 in Q2 2025, and anticipates significant milestones that could drive value for stakeholders.